Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
|Articles|February 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 2
- Volume 17
- Issue 2
M.D. Anderson and AstraZeneca form neuropathic pain alliance
M.D. Anderson Cancer Center and AstraZeneca will collaborate to help advance the understanding of neuropathic pain caused by cancer chemotherapy.
Advertisement
HOUSTONM.D. Anderson Cancer Center and AstraZeneca will collaborate to help advance the understanding of neuropathic pain caused by cancer chemotherapy. The alliance will focus on identifying neurobiological differences between cancer patients who develop such pain and those who do not, and better understanding the mechanisms through which chemotherapies cause peripheral nerve dysfunctions.
Articles in this issue
almost 19 years ago
NLST article not balanced, critic of screening trial assertsalmost 19 years ago
Good nilotinib responses in imatinib-resistant AP-CMLalmost 19 years ago
Virus linked to Merkel cell carcinomaalmost 19 years ago
Benefit of adjuvant RT/CT for pancreatic ca affirmedalmost 19 years ago
Recurrence Score helps select node+ pts for chemoalmost 19 years ago
For resectable liver mets: Preop chemotherapy or not?almost 19 years ago
Plerixafor boosts stem cell mobilization in myeloma ptsalmost 19 years ago
MRI shows second-hand smoke damagealmost 19 years ago
Assay has high sensitivity for hard-to-detect SLN metsalmost 19 years ago
Dasatinib effective in imatinib resistant/intolerant CMLAdvertisement
Related to this article
Joshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.
The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
Sac-TMT Earns FDA Priority Review in Pretreated Endometrial Cancer
3
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
4
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple Myeloma
5